Publications by authors named "N Finn"

Infections are a significant cause of morbidity and mortality in myelodysplastic syndrome (MDS). Precise estimates of infection frequency and severity with modern therapies are uncertain. We conducted a retrospective analysis of a prospective cohort enrolled in a Canadian MDS registry and characterized the frequency and severity of infectious complications.

View Article and Find Full Text PDF
Article Synopsis
  • Myelodysplastic syndromes (MDSs) treatment aims to improve patients' quality of life (QOL), especially concerning issues such as anemia and transfusion dependence.
  • A study involving 1120 MDS patients revealed that those who maintained transfusion independence (TI) had better overall survival (OS) and QOL compared to those remaining transfusion dependent (TD), while those switching between these statuses had intermediate results.
  • Specifically, patients who transitioned from TD to TI experienced improved QOL, while those moving to TD reported declines in their global QOL, especially in areas like fatigue and daily functioning.
View Article and Find Full Text PDF

Background: There is little evidence on variation in radiotherapy use in different countries, although it is a key treatment modality for some patients with cancer. Here we aimed to examine such variation.

Methods: This population-based study used data from Norway, the four UK nations (England, Northern Ireland, Scotland, and Wales), nine Canadian provinces (Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan), and two Australian states (New South Wales and Victoria).

View Article and Find Full Text PDF

Background: There are few data on international variation in chemotherapy use, despite it being a key treatment type for some patients with cancer. Here, we aimed to examine the presence and size of such variation.

Methods: This population-based study used data from Norway, the four UK nations (England, Northern Ireland, Scotland, and Wales), eight Canadian provinces (Alberta, British Columbia, Manitoba, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan), and two Australian states (New South Wales and Victoria).

View Article and Find Full Text PDF

Background: Asciminib is a novel drug specifically targeting ABL myristoyl pocket in the ABL1 protein.

Methods: Forty one patients with chronic myeloid leukemia treated with asciminib from 2018 to 2022 were reviewed and analyzed for the efficacy and tolerability of asciminib using real-world experience data.

Results: The median age was 60 years (range 17-90) with a past history of a cardiovascular event in 21 patients (51%).

View Article and Find Full Text PDF